← Leaderboards
Janet E. McElhaney
Eastern Virginia Medical School
$7,965,444
Attributed
$8,994,394
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $860.8K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$8,994,394 · 10
By mechanism
R01$5,276,691 · 3
P01$1,660,479 · 1
U01$1,289,741 · 1
M01$767,483 · 5
Top collaborators
- George A Kuchel6 shared
Others in their field
Top investigators on “Influenza”
- Richard Webby · St. Jude Children'S Research Hospital$247,579,041
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$102,941,847
- Adolfo Garcia-Sastre · Jackson Laboratory$94,049,184
- Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai$72,751,763
- John Beigel · Leidos Biomedical Research, Inc.$72,410,171
- Ted Ross · University Of Georgia$71,962,304
Research focus
InfluenzaHospitalizationVaccinationElderlyResponseVaccine EfficacyInfluenza VaccinationVaccinesT-LymphocyteAgingImmune ResponseCytokineInflammatoryAge RelatedDeath RateProgramsPeripheral Blood Mononuclear CellImmune FunctionInfluenza Virus VaccineAgedCessation Of LifeAffectCommunicable DiseasesCytotoxic T-Lymphocytes
Grant awards (32)
Immune Response to High-Dose vs. Standard Dose Influenza Vaccine$366,810
R01 · FY2018 · AG
Immune Response to High-Dose vs. Standard Dose Influenza Vaccine$376,617
R01 · FY2017 · AG
Immune Response to High-Dose vs. Standard Dose Influenza Vaccine$386,287
R01 · FY2016 · AG
Impact of aging T cell responses to influenza vaccination$351,524
P01 · FY2016 · AG · contact PI
Immune Response to High-Dose vs. Standard Dose Influenza Vaccine$123,000
R01 · FY2016 · AG
Immune Response to High-Dose vs. Standard Dose Influenza Vaccine$384,020
R01 · FY2015 · AG
Impact of aging T cell responses to influenza vaccination$342,974
P01 · FY2015 · AG · contact PI
Immune Response to High-Dose vs. Standard Dose Influenza Vaccine$421,167
R01 · FY2014 · AG
Impact of aging T cell responses to influenza vaccination$351,522
P01 · FY2014 · AG · contact PI
Impact of aging T cell responses to influenza vaccination$334,110
P01 · FY2013 · AG · contact PI
Impact of aging T cell responses to influenza vaccination$280,349
P01 · FY2012 · AG · contact PI
Adjuvants and Virosomal Vaccines for the Elderly$262,580
U01 · FY2011 · AI · contact PI
Adjuvants and Virosomal Vaccines for the Elderly$265,232
U01 · FY2010 · AI · contact PI
T-Cell Responses Predict Influenza Risk in Older Adults$262,192
R01 · FY2010 · AI · contact PI
T-Cell Responses Predict Influenza Risk in Older Adults$470,418
R01 · FY2009 · AI · contact PI
Adjuvants and Virosomal Vaccines for the Elderly$259,726
U01 · FY2009 · AI · contact PI
T-Cell Responses Predict Influenza Risk in Older Adults$405,725
R01 · FY2008 · AI · contact PI
Adjuvants and Virosomal Vaccines for the Elderly$252,455
U01 · FY2008 · AI · contact PI
INFLUENZA RISK$137,338
M01 · FY2008 · RR · contact PI
T-Cell Responses Predict Influenza Risk in Older Adults$413,917
R01 · FY2007 · AI · contact PI
Adjuvants and Virosomal Vaccines for the Elderly$249,748
U01 · FY2007 · AI · contact PI
INFLUENZA RISK$88,148
M01 · FY2007 · RR · contact PI
T-Cell Responses Predict Influenza Risk in Older Adults$418,738
R01 · FY2006 · AI · contact PI
INFLUENZA RISK$198,010
M01 · FY2006 · RR · contact PI
EFFECTS OF AGING$7,226
M01 · FY2006 · RR · contact PI
T-Cell Responses Predict Influenza Risk in Older Adults$314,500
R01 · FY2005 · AI
INFLUENZA RISK$249,650
M01 · FY2005 · RR
T-Cell Responses Predict Influenza Risk in Older Adults$326,250
R01 · FY2004 · AG
Influenza Risk$87,111
M01 · FY2004 · RR
T-Cell Responses Predict Influenza Risk in Older Adults$218,292
R01 · FY2003 · AG
T-Cell Responses Predict Influenza Risk in Older Adults$85,233
R01 · FY2003 · AG
T-Cell Responses Predict Influenza Risk in Older Adults$303,525
R01 · FY2002 · AG